Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

Michael A. Carducci, MD, discusses the significance of two ongoing clinical trials in prostate cancer: the phase 3 CAPItello-280 trial (NCT05348577) and phase 3 INDICATE study (EA8191; NCT04423211).

The combination of nivolumab and relatlimab demonstrated clinical benefit with a manageable safety profile in patients with advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression, according to findings from the ongoing phase 1/2a RELATIVITY-020 trial.

Julie Renee Brahmer, MD, discusses clinical trials investigating treatment options for patients with non–small cell lung cancer following progression after first-line immunotherapy.

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

With acquired resistance patterns emerging for nearly every agent, hematologic experts are looking closely at sequencing patterns, but more work needs to be done in aggressive malignancies in which mutations associated with resistance may be present before therapy even begins.

Tania Jain, MBBS, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors in myelofibrosis.

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Haploidentical donors and posttransplant cyclophosphamide is a comparable alternative to matched unrelated donors for patients with myelofibrosis receiving blood or marrow transplant without matched sibling donors, although matched sibling donors, when available, remain the preferred donor option.

Treatment with neoadjuvant nivolumab led to encouraging 5-year recurrence-free survival and overall survival rates compared with historical outcomes in patients with non–small cell lung cancer who underwent surgical resection.

Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.

Alexander Spira, MD, PhD, FACP, highlights the top advancements across non–small cell lung cancer in 2022, emphasized the need for increased genetic testing to inform treatment decisions, and previewed other agents under development.

Evan J. Lipson, MD, expands on key takeaways from the NEOpredict-Lung trial, the additional benefit that PICIT may offer to patients who progress on other immunotherapies, and the effect that both NEOpredict-Lung and RELATIVITY-047 have on the role of immunotherapy in the lung and melanoma treatment paradigms.

Benjamin P. Levy, MD; Bhuvana Ramkumar, MD; and Neil Morganstein, MD, discuss the challenges with tissue testing facing care teams, as well as multilevel hurdles in procurement, analysis of results, and insurance.

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

Kara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.

Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).

Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical records, how they address non–small cell lung cancer test results with patients, and their hopes for the future of pathology at their institutions.

Cesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.

A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.

Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.

Benjamin Levy, MD, discusses the significance of the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Benjamin Levy, MD, discusses treatment considerations for the integration of trastuzumab deruxtecan into practice and what this approval signals for the future of the field.

The combination of datopotamab deruxtecan and pembrolizumab, with or without platinum-based chemotherapy, displayed promising efficacy and a manageable safety profile in patients with advanced/metastatic non–small cell lung cancer.

Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.